Patients in England are given green light to buy drugs privately alongside NHS careBMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a2418 (Published 05 November 2008) Cite this as: BMJ 2008;337:a2418
- Zosia Kmietowicz
Patients in England will be able to top up their treatment with drugs bought privately and yet continue to receive NHS care, provided that they have their top-up treatment administered in a non-NHS setting, the health secretary announced this week.
The change in rules on top-up drugs, which has immediate effect, is part of a package of 14 recommendations made by Mike Richards, England’s national clinical director for cancer, in his review of copayments, all of which the government has accepted.
Taken together the new plans will reduce the number of people seeking private drug treatment from the estimated 5000 patients a year currently to a few hundred people, predicted Professor Richards.
New guidance, which is being sent to all trusts and commissioners in England, says that patients may pay for additional private healthcare while continuing to receive care from the NHS but that there should be no risk of the NHS subsidising their private care. Patients who opt to buy drugs privately will need to pay for any predictable related costs, such as antiemetic drugs, heart scans, and pharmacy and nursing costs, although any unpredictable costs, such as from side effects of drugs, will be covered by the NHS.
The health secretary, Alan Johnson, asked Professor Richards in June to review the rule after …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial